Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature
ConclusionsTMZ may be useful and well-tolerated in APAs and PCs as a long-term therapy. PR appears within the first cycles with no escape throughout the treatment; most patients achieve SD. We suggest extended protocols particularly in responsive ACTH+ PAs and PCs, when further therapies may be unsuccessful.
Source: Pituitary - Category: Endocrinology Source Type: research
More News: Brain | Cancer & Oncology | Carcinoma | Endocrinology | Neurology | Neurosurgery | Study | Temodar | Toxicology